➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
McKesson
Colorcon
McKinsey

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Deoxythymidine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Deoxythymidine?

Deoxythymidine is an investigational drug.

There have been 9 clinical trials for Deoxythymidine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Infection. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Modis Therapeutics, Inc., and Bristol-Myers Squibb.

There are two US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for Deoxythymidine
TitleSponsorPhase
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) DeficiencyZogenix, Inc.Phase 3
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) DeficiencyModis Therapeutics, Inc.Phase 3
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2Modis Therapeutics, Inc.Phase 2

See all Deoxythymidine clinical trials

Clinical Trial Summary for Deoxythymidine

Top disease conditions for Deoxythymidine
Top clinical trial sponsors for Deoxythymidine

See all Deoxythymidine clinical trials

US Patents for Deoxythymidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Deoxythymidine   Start Trial Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (Brussels, BY) KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (Leuven, BE)   Start Trial
Deoxythymidine   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
Deoxythymidine   Start Trial Use of small molecules to enhance MAFA expression in pancreatic endocrine cells Janssen Biotech, Inc. (Horsham, PA)   Start Trial
Deoxythymidine   Start Trial Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom MERIAL, INC. (Duluth, GA)   Start Trial
Deoxythymidine   Start Trial Alphaviral vectors and cell lines for producing recombinant proteins 3P BIOPHARMACEUTICALS, S.L. (Noain (Navarra), ES)   Start Trial
Deoxythymidine   Start Trial Method for high throughput screening of nucleic acids Complete Genomics, Inc. (San Jose, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Deoxythymidine

Drugname Country Document Number Estimated Expiration Related US Patent
Deoxythymidine Brazil BR112016029632 2034-06-17   Start Trial
Deoxythymidine Canada CA2951349 2034-06-17   Start Trial
Deoxythymidine China CN106559992 2034-06-17   Start Trial
Deoxythymidine European Patent Office EP3157924 2034-06-17   Start Trial
Deoxythymidine United Kingdom GB201410817 2034-06-17   Start Trial
Deoxythymidine Japan JP2017518385 2034-06-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
McKesson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.